EP1589955B1 - Systeme therapeutique transdermique apte a une application thermique visant a augmenter la permeation de substances actives, et utilisation associee - Google Patents

Systeme therapeutique transdermique apte a une application thermique visant a augmenter la permeation de substances actives, et utilisation associee Download PDF

Info

Publication number
EP1589955B1
EP1589955B1 EP04707525A EP04707525A EP1589955B1 EP 1589955 B1 EP1589955 B1 EP 1589955B1 EP 04707525 A EP04707525 A EP 04707525A EP 04707525 A EP04707525 A EP 04707525A EP 1589955 B1 EP1589955 B1 EP 1589955B1
Authority
EP
European Patent Office
Prior art keywords
tts
active substance
skin
polysiloxane
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP04707525A
Other languages
German (de)
English (en)
Other versions
EP1589955A2 (fr
Inventor
Walter Müller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LTS Lohmann Therapie Systeme AG
Original Assignee
LTS Lohmann Therapie Systeme AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102004003224A external-priority patent/DE102004003224A1/de
Application filed by LTS Lohmann Therapie Systeme AG filed Critical LTS Lohmann Therapie Systeme AG
Priority to EP06017854A priority Critical patent/EP1726302A2/fr
Publication of EP1589955A2 publication Critical patent/EP1589955A2/fr
Application granted granted Critical
Publication of EP1589955B1 publication Critical patent/EP1589955B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide

Definitions

  • Transdermal Therapeutic Systems have become a well-established drug that is well accepted by patients for its therapeutic benefits.
  • TTS Transdermal Therapeutic Systems
  • transdermal delivery of topical and systemic agents is limited to substances that can permeate through the skin in an pharmacologically acceptable amount due to their efficacy at even low doses and their physicochemical properties ,
  • transdermal system that takes advantage of this effect is described in US Pat. No. 4,898,592.
  • the transdermal system described therein optionally includes a heat-conducting layer to utilize the body heat to raise the temperature at the site of application of the TTS.
  • U.S. Patent No. 5,919,479 describes a principle which discloses the application of controlled heat in combination with the use of local anesthetics.
  • the heat is generated by the reaction of atmospheric oxygen with activated carbon pyrophoric iron in the presence of water.
  • a TTS which contains a backing layer, a matrix layer based on polysiloxane and a protective layer.
  • the object of this invention is therefore to develop formulations for the active ingredient-containing parts of a matrix system, which are particularly well suited to increase the release of active ingredient for the whole or part of the application time by the application of heat.
  • matrix systems merely consist of an active substance-impermeable backing layer, a matrix layer containing active substance and, ideally, self-adhesive, and a protective layer to be removed before use.
  • the active ingredient-containing layer usually consists in addition to the active ingredient for the most part of polymers based on polyacrylates, polyisobutylene, polyisoprene, block polymers of styrene-polybutylene-styrene, polysiloxanes, polyurethanes or hydrogels.
  • matrices based on polyisobutylene and block polymers contain additional tackifiers based on hydrocarbon resins and / or rosin derivatives. All matrices may contain additional adjuvants that affect the solubility of the drug, or permeation enhancers that increase the rate of absorption from the system.
  • the drug uptake is usually controlled less by the system but to a large extent by the skin itself.
  • the skin side with a control membrane and the membrane optionally with an adhesive layer for anchoring the system to the skin provided in order to achieve a better system control.
  • the skin-side adhesive layer for anchoring on the skin can also be loaded with active ingredient. This portion is then delivered without membrane control, e.g. To saturate a possible skin depot for the active ingredient as quickly as possible.
  • thermodynamic activity of the active substance is the decisive parameter determining the release rate for the in vivo release of active ingredient in simple monolytic matrix systems.
  • the maximum thermodynamic activity is achieved when the concentration of the active ingredient corresponds to the saturation concentration of the active ingredient in the matrix formulation.
  • a further increase in the active ingredient concentration does not lead to a further increase in the thermodynamic activity when the content of the active ingredient exceeding the saturation solubility is present in the matrix as pure active ingredient, ie in the form of crystals or, in the case of low-melting active ingredients, as a liquid phase.
  • the active ingredient is dissolved in an amount exceeding the saturation concentration in the system, it is called supersaturated systems. Since the active ingredient in such systems tends to recrystallise during storage or to form its own phase, such systems must be regarded as meta- or unstable.
  • transdermal therapeutic system according to claim 1 of the present application.
  • the TTS of the invention e.g. B. in the form of a matrix layer, an internal heat-emitting element.
  • a preferred embodiment of the present invention is a TTS which is connected to an external heat-emitting element, a so-called heat pack, which can be removed or replaced without damaging the transdermal system.
  • This element can according to a further embodiment also be separate from the TTS, but in a common packaging unit.
  • the present invention furthermore relates to the use of the above-defined TTS for the transdermal administration of active ingredients at temperatures higher than the skin temperature, characterized in that, after removal of the protective layer, the matrix layer covered by the backing layer is applied to the skin and either by an internal heat-emitting element or by bonding the TTS to an external heat-emitting element (so-called heatpack), the matrix layer is heated for a certain time to a temperature higher than the skin temperature. In a preferred embodiment of the use, the matrix is heated to a temperature up to and including 50 ° C.
  • the subject of the present invention is also a packaging unit in which the TTS and the external heat-emitting element (heat pack) are packaged separately from each other.
  • Internal or external heat-emitting elements according to the invention may be those of the type described, for example. As described in US Pat. Nos. 5,919,479 and 6,261,595, respectively.
  • Polysiloxanes (to be more specific: polyorganosiloxanes) are available in the form of solutions or as solvent-free two-component systems. Due to the variation of the organic part of the polysiloxanes, there are a large number of different polysiloxanes, but only polydimethylsiloxanes have hitherto been used for transdermal systems.
  • the polysiloxane In two-component systems, the polysiloxane has a relatively low molecular weight and is liquid to viscous at room temperature. Only when combining the two components is a cross-linking each leading to a usable product.
  • the methyl groups may be wholly or partly replaced by other alkyl or phenyl radicals.
  • the molecular weight and degree of crosslinking are important parameters that determine the cohesion and tack of the polymer after removal of the solvent.
  • polysiloxanes are characterized by good skin compatibility, low solubility for most active ingredients and an extremely high diffusion coefficient for the dissolved portion of the active ingredient.
  • the low dissolving capacity and the high diffusion coefficient are of particular importance.
  • the TTS and thus the matrix is heated to temperatures up to 50 ° C. It is without exception assumed that the increase in temperature results in an increase in the saturation solubility of the active ingredient and an increase in the concentration of the dissolved active ingredient. Since this increases the thermodynamic activity of the drug in the matrix and the diffusion coefficient of the drug in the stratum corneum, the rate of delivery of the drug from the TTS to the organism increases.
  • TTS which represents the worst case of a TTS based on a silicone adhesive in the sense of this invention, is compared with a thoroughly typical TTS based on polyacrylate adhesives.
  • TTS area 10 cm 2
  • Drug loading 20 mg / TTS Saturation solubility in Sililconsystem: 5% (g / g)
  • Coating weight silicone system 80 g / m 2
  • Saturation solubility in polyacrylate system 20%
  • Coating Weight Polyacrylate System 50 g / m 2
  • Drug delivery 50 ⁇ g / h
  • Temperature increase 32 ° C ⁇ 40 ° C
  • Increasing the saturation solubility at 40 ° C 10% Silicone TTS Polyacrylate
  • TTS Weight of the matrix 16 mg 10 mg drug loading 4 mg 4 mg of which dissolved at 32 ° C 0.8 mg 1) 2 (mg 2) of which dissolved at 40 ° C 0.88 mg 2.2 mg
  • Time to return to saturation solubility at 32 ° C 3) 1.6 hours 4.0 hours 1) saturation solubility 5% by weight; corresponds to 20% of the total amount of active ingredient 2)
  • Saturation solubility 20% by weight corresponds to 50% of the total amount of active ingredient 3)
  • undersaturated systems are largely unusable in conjunction with heat applications to increase permeation rates when a constant release of active ingredient is required over the application period between the heat application phases.
  • Only systems with a high drug loading and a low drug delivery are suitable under this condition, since under these conditions, the drug concentration and thus the release rate changes relatively little during the application time or by the increased drug delivery during heat application.
  • TTS can be prepared by suspending the active ingredient in the solution of the polysiloxane, adding all other excipients and homogenizing the mass by stirring. After coating on a suitable film, the solvent of the adhesive is evaporated and the dried film is laminated with the backing layer of the TTS. The finished TTS are then punched out of this laminate.
  • Example 1 with fentanyl as the base.
  • Example 2 describes the preparation of a TTS with an additional control membrane.
  • Example 1 TTS with fentanyl as active ingredient without control membrane
  • fentanyl base 3 g are added to 138 g of a 70 percent solution of a silicone adhesive in n-heptane (BIO-PSA 4301, Dow Corning) and suspended in this solution by stirring.
  • the suspension is then coated on a suitable redetachable protective film (Scotchpak 1022, 3M) to a thickness such that, after removal of the solvent, a coating weight of 100 g / m 2 results.
  • the dried film is now laminated with a 23 micron thick polyester film, the backing layer of the TTS, and punched out of this laminate, the TTS.
  • the individual TTS are packed in a bag made of a heat-sealable packaging material.
  • Example 2 TTS with fentanyl as a control membrane drug
  • fentanyl base 3 g are added to 138 g of a 70 percent solution of a silicone adhesive in n-heptane (BIO-PSA 4301, Dow Corning) and suspended in this solution by stirring.
  • the suspension is then coated on a suitable redetachable protective film (Scotchpak 1022, 3M) to a thickness such that, after removal of the solvent, a coating weight of 100 g / m 2 results.
  • the dried film is now laminated with a 23 ⁇ m thick polyester film, the backing layer of the TTS.
  • control membrane 50 ⁇ m thick EVA film with a vinyl acetate content of 19%) is now laminated onto the dried film.
  • the removable protective film is peeled off and laminated onto the membrane of the skin adhesive layer prepared under b.
  • the individual TTSs are punched out of the total laminate and packaged in a bag made of a heat-sealable packaging laminate.

Claims (14)

  1. Système thérapeutique transdermique (TTS) pour une délivrance à taux temporairement augmenté d'au moins un principe actif pharmacologique par réchauffage du TTS à une température comprise entre la température de la peau et 50°C compris, et par refroidissement du TTS après une durée déterminée à la température de la peau, comprenant au moins une couche arrière imperméable au principe actif, au moins une couche matricielle à base d'au moins un polysiloxane renfermant le ou lés principes actifs pharmacologiques cités ci-dessus, une couche protectrice amovible, ainsi qu'un élément interne et/ou externe fournissant la chaleur,
    (a) la couche matricielle renfermant le principe actif est constituée, sans la prise en compte du principe actif, par au moins 80 % en masse d'un polysiloxane,
    (b) le principe actif se présente sous forme dissoute à 20 % en masse au maximum, et
    (c) le principe actif dans ce polysiloxane possède une solubilité de saturation d'au maximum 5 %,
    caractérisé en ce que, après avoir terminé le réchauffage du TTS, l'activité thermodynamique du principe actif dans la couche matricielle revient rapidement au niveau de départ.
  2. TTS selon la revendication 1, caractérisé en ce que le polysiloxane est un polydialkylsiloxane, dans lequel un ou plusieurs groupes alkyle peuvent être remplacés par des restes phényle.
  3. TTS selon l'une des revendications précédentes, caractérisé en ce que le polysiloxane est résistant aux amines.
  4. TTS selon une ou plusieurs des revendications précédentes, caractérisé en ce que le polysiloxane possède des propriétés autocollantes.
  5. TTS selon une ou plusieurs des revendications précédentes, caractérisé en ce que le polysiloxane est un polydiméthylsiloxane.
  6. TTS selon une ou plusieurs des revendications précédentes, caractérisé en ce que la couche renfermant le principe actif est munie du côté de contact avec la peau d'une membrane de contrôle et celle-ci est facultativement pourvue d'une couche adhésive afin qu'elle soit fixée à la peau.
  7. TTS selon la revendication 8, caractérisé en ce que la couche adhésive prévue pour la fixation à la peau est également chargée du principe actif.
  8. TTS selon une ou plusieurs des revendications précédentes, caractérisé en ce que la couche renfermant le principe actif renferme une matière auxiliaire réduisant les propriétés barrière de la peau.
  9. TTS selon la revendication 10, caractérisé en ce que la matière auxiliaire réduisant les propriétés barrière de la peau est l'acide oléique.
  10. TTS selon une ou plusieurs des revendications précédentes, caractérisé en ce que le principe actif est un analgésique à efficacité topique ou systémique.
  11. TTS selon la revendication 12, caractérisé en ce que le principe actif est le fentanyle ou une substance analogue au fentanyle, le butorphanol, l'oxycodone, le kétorolac, la buprénorphine, la morphine, la tétracaïne, la lidocaïne, la bupivacaïne, la prilocaïne ou la benzocaïne.
  12. TTS selon une ou plusieurs des revendications précédentes, caractérisé en ce que le principe actif est un agent anti-parkinsonien, un sérum de vaccination, un broncholytique, un antiépileptique ou un agent antidépendance.
  13. TTS selon la revendication 11, caractérisé en ce que le principe actif est le fentanyle et/ou une substance analogue au fentanyle.
  14. Unité d'emballage, caractérisée en ce qu'elle emballe individuellement
    a) un TTS selon la revendication 1 mais sans l'élément interne et sans l'élément externe fournissant la chaleur, et
    b) un ou plusieurs éléments externes fournissant la chaleur.
EP04707525A 2003-02-07 2004-02-03 Systeme therapeutique transdermique apte a une application thermique visant a augmenter la permeation de substances actives, et utilisation associee Expired - Lifetime EP1589955B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06017854A EP1726302A2 (fr) 2003-02-07 2004-02-03 Système thérapeutique transdermique apte à une application thermique visant à augmenter la perméation des substances actives, et utilisation associée

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE10304989 2003-02-07
DE10304989 2003-02-07
DE102004003224A DE102004003224A1 (de) 2003-02-07 2004-01-22 Für die Wärmeanwendung zur Beschleunigung der Permeation von Wirkstoffen geeignetes transdermales System und seine Verwendung
DE102004003224 2004-01-22
PCT/EP2004/000944 WO2004069286A2 (fr) 2003-02-07 2004-02-03 Systeme therapeutique transdermique apte a une application thermique visant a augmenter la permeation de substances actives, et utilisation associee

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP06017854A Division EP1726302A2 (fr) 2003-02-07 2004-02-03 Système thérapeutique transdermique apte à une application thermique visant à augmenter la perméation des substances actives, et utilisation associée

Publications (2)

Publication Number Publication Date
EP1589955A2 EP1589955A2 (fr) 2005-11-02
EP1589955B1 true EP1589955B1 (fr) 2006-11-02

Family

ID=32851838

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04707525A Expired - Lifetime EP1589955B1 (fr) 2003-02-07 2004-02-03 Systeme therapeutique transdermique apte a une application thermique visant a augmenter la permeation de substances actives, et utilisation associee

Country Status (16)

Country Link
US (1) US20060078600A1 (fr)
EP (1) EP1589955B1 (fr)
JP (1) JP2006517124A (fr)
KR (1) KR20050099537A (fr)
AT (1) ATE344024T1 (fr)
AU (1) AU2004210406B2 (fr)
BR (1) BRPI0407323A (fr)
CA (1) CA2513402A1 (fr)
DE (1) DE502004001897D1 (fr)
DK (1) DK1589955T3 (fr)
ES (1) ES2274424T3 (fr)
MX (1) MXPA05008366A (fr)
NZ (1) NZ541576A (fr)
PL (1) PL378076A1 (fr)
RU (1) RU2348397C2 (fr)
WO (1) WO2004069286A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004044578A1 (de) * 2004-09-13 2006-03-30 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit einer Haftschicht, Verfahren zum Silikonisieren einer Rückschicht des Systems und Verwendung der Rückschicht
JP4815163B2 (ja) * 2005-07-26 2011-11-16 久光製薬株式会社 粘着剤及び貼付剤
DE102006054733A1 (de) * 2006-11-21 2008-05-29 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches Systems mit hoher Wirkstoffausnutzungsrate und Dosiergenauigkeit
WO2010114973A1 (fr) * 2009-04-01 2010-10-07 Jie Zhang Méthodes de traitement des douleurs myofasciales, musculaires et/ou dorsales
US9186334B2 (en) 2009-05-04 2015-11-17 Nuvo Research Inc. Heat assisted lidocaine and tetracaine for transdermal analgesia
CN102427792A (zh) * 2009-05-04 2012-04-25 扎斯制药公司 治疗与神经瘤、神经卡压及其他病况相关联的疼痛的方法
WO2011028542A2 (fr) * 2009-08-24 2011-03-10 Zars Pharma, Inc. Méthodes de traitement de la douleur associée à un syndrome de douleur régional complexe
US20180360769A1 (en) * 2015-11-30 2018-12-20 Elliptical Therapeutics, Llc Systems and methods for transdermal drug delivery
WO2018123822A1 (fr) 2016-12-28 2018-07-05 久光製薬株式会社 Timbre contenant du butorphanol
EP3612170A4 (fr) * 2017-04-19 2021-01-27 Inep Europe Sarl Procédé de fabrication d'un timbre transdermique de fentanyl avec distribution uniforme de cristaux de médicament
EP3616699B1 (fr) 2017-04-25 2021-06-09 Hisamitsu Pharmaceutical Co., Inc. Patch adhésif
WO2018198924A1 (fr) 2017-04-25 2018-11-01 久光製薬株式会社 Patch adhésif

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4230105A (en) * 1978-11-13 1980-10-28 Merck & Co., Inc. Transdermal delivery of drugs
JPS60185713A (ja) * 1984-03-05 1985-09-21 Nitto Electric Ind Co Ltd 経皮吸収性製剤及びその製法
US4588580B2 (en) * 1984-07-23 1999-02-16 Alaz Corp Transdermal administration of fentanyl and device therefor
US4655767A (en) * 1984-10-29 1987-04-07 Dow Corning Corporation Transdermal drug delivery devices with amine-resistant silicone adhesives
EP0258521B1 (fr) * 1986-08-23 1990-05-02 Arno Walter Latzke Dispositif pour appliquer des agents par diffusion à travers la peau
US4906463A (en) * 1986-12-22 1990-03-06 Cygnus Research Corporation Transdermal drug-delivery composition
JPS63307819A (ja) * 1987-06-08 1988-12-15 Sekisui Chem Co Ltd 経皮吸収貼付剤
US4830855A (en) * 1987-11-13 1989-05-16 Landec Labs, Inc. Temperature-controlled active agent dispenser
DK0695177T3 (da) * 1993-04-20 1998-09-28 Hexal Ag Plaster indeholdende aktivt stof
US6245347B1 (en) * 1995-07-28 2001-06-12 Zars, Inc. Methods and apparatus for improved administration of pharmaceutically active compounds
US5658583A (en) * 1995-07-28 1997-08-19 Zhang; Jie Apparatus and methods for improved noninvasive dermal administration of pharmaceuticals
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE19923427A1 (de) * 1999-05-21 2000-11-23 Lohmann Therapie Syst Lts Vorrichtung und Verfahren zur Steigerung der transdermalen Permeation von Arzneistoffen
EP1280485A4 (fr) * 2000-02-29 2006-11-29 Zars Inc Timbre transdermique pour medicament ameliore
US6261595B1 (en) * 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
PL363079A1 (en) * 2001-03-16 2004-11-15 Alza Corporation Transdermal patch for administering fentanyl
DE10141651B4 (de) * 2001-08-24 2007-02-15 Lts Lohmann Therapie-Systeme Ag Transdermales Therapeutisches System (TTS) mit dem Wirkstoff Fentanyl und Verfahren zu seiner Herstellung
US20040086551A1 (en) * 2002-10-30 2004-05-06 Miller Kenneth J. Fentanyl suspension-based silicone adhesive formulations and devices for transdermal delivery of fentanyl

Also Published As

Publication number Publication date
PL378076A1 (pl) 2006-02-20
RU2348397C2 (ru) 2009-03-10
JP2006517124A (ja) 2006-07-20
KR20050099537A (ko) 2005-10-13
NZ541576A (en) 2008-03-28
WO2004069286A3 (fr) 2004-11-25
MXPA05008366A (es) 2005-11-04
AU2004210406B2 (en) 2008-10-09
DK1589955T3 (da) 2007-03-12
DE502004001897D1 (de) 2006-12-14
EP1589955A2 (fr) 2005-11-02
US20060078600A1 (en) 2006-04-13
RU2005127809A (ru) 2006-01-27
ES2274424T3 (es) 2007-05-16
CA2513402A1 (fr) 2004-08-19
BRPI0407323A (pt) 2006-02-21
ATE344024T1 (de) 2006-11-15
WO2004069286A2 (fr) 2004-08-19
AU2004210406A1 (en) 2004-08-19

Similar Documents

Publication Publication Date Title
DE69822199T2 (de) Arzneimittel und verfahren zur behandlung von aufmerksamkeitsstörungen und aufmerksamkeits-/hyperaktivitätsstörungen mit methylphenidat
DE69637061T2 (de) Zusammensetzung und Vorrichtung zur Verabreichung von Pergolid in einer therapeutisch wirksamen Rate
DE10141651B4 (de) Transdermales Therapeutisches System (TTS) mit dem Wirkstoff Fentanyl und Verfahren zu seiner Herstellung
DE60314298T2 (de) Therapeutisches pflaster mit capsaicin-haltiger polysiloxan-matrix
DE69916492T2 (de) Pflaster zur transdermalen applikation von flüchtigen, flüssigen wirkstoffen
DE19958554C2 (de) Mikroreservoirsystem auf Basis von Polysiloxanen und ambiphilen Lösemitteln und ihre Herstellung
EP1589955B1 (fr) Systeme therapeutique transdermique apte a une application thermique visant a augmenter la permeation de substances actives, et utilisation associee
CA1059909A (fr) Systeme therapeutique pour administrer de la scopolamine par voie transcutanee
EP1191927B1 (fr) Systeme a microreservoir, a base de polysiloxanes et de solvants hydrophiles et lipophiles
DE60311449T2 (de) Transdermales therapeutisches system mit zwei übereinanderliegenden matrixschichten, die verschiedene affinitäten zum enthaltenen wirkstoff ausweisen
EP2217206B1 (fr) Système thérapeutique transdermique contenant un modulateur de récepteurs nicotiques d'acétylcholine (nachr)
DE3905051A1 (de) Therapeutisches system zur verzoegerten und gesteuerten transdermalen oder transmucosalen verabreichung von wirkstoffen (i)
JP3715361B2 (ja) 経皮用粘着剤組成物及びその製法
DE10004790A1 (de) Transdermales therapeutisches System zur Verabreichung von Zaleplon
EP1726302A2 (fr) Système thérapeutique transdermique apte à une application thermique visant à augmenter la perméation des substances actives, et utilisation associée
EP2366388A1 (fr) Système thérapeutique transdermique non occlusif destiné à l'administration de buprenorphine
EP0659079B1 (fr) Systeme therapeutique percutane contenant du pentylenetetrazol comme principe actif
Gupta Transdermal drug delivery system
DE102021128912A1 (de) Okklusives pflaster mit flexibler backing
CN116056689A (zh) 艾司氯胺酮-混悬剂-tts
DE102006011340A1 (de) Wirkstoffhaltige Pflaster mit verbesserter Handhabung
EP1459741A1 (fr) Compositions et procédés de traitement du trouble déficitaire de l'attention et de l'hyperactivité avec déficit de l'attention au moyen du méthylphénidate

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050726

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20061102

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20061102

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: LANGUAGE OF EP DOCUMENT: GERMAN

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REF Corresponds to:

Ref document number: 502004001897

Country of ref document: DE

Date of ref document: 20061214

Kind code of ref document: P

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20070109

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070202

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20070400088

Country of ref document: GR

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E000732

Country of ref document: EE

Effective date: 20061213

GBT Gb: translation of ep patent filed (gb section 77(6)(a)/1977)

Effective date: 20070206

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070228

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E001210

Country of ref document: HU

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2274424

Country of ref document: ES

Kind code of ref document: T3

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20070803

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20061102

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20110218

Year of fee payment: 8

Ref country code: HU

Payment date: 20110225

Year of fee payment: 8

Ref country code: DK

Payment date: 20110210

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20110216

Year of fee payment: 8

Ref country code: FR

Payment date: 20110302

Year of fee payment: 8

Ref country code: IT

Payment date: 20110219

Year of fee payment: 8

Ref country code: EE

Payment date: 20110211

Year of fee payment: 8

Ref country code: FI

Payment date: 20110214

Year of fee payment: 8

Ref country code: LU

Payment date: 20110225

Year of fee payment: 8

Ref country code: CZ

Payment date: 20110131

Year of fee payment: 8

Ref country code: CH

Payment date: 20110222

Year of fee payment: 8

Ref country code: AT

Payment date: 20110214

Year of fee payment: 8

Ref country code: DE

Payment date: 20110218

Year of fee payment: 8

Ref country code: RO

Payment date: 20110131

Year of fee payment: 8

Ref country code: TR

Payment date: 20110127

Year of fee payment: 8

Ref country code: SE

Payment date: 20110214

Year of fee payment: 8

Ref country code: PT

Payment date: 20110124

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20110218

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20110217

Year of fee payment: 8

Ref country code: BE

Payment date: 20110211

Year of fee payment: 8

Ref country code: ES

Payment date: 20110222

Year of fee payment: 8

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20120803

BERE Be: lapsed

Owner name: LTS LOHMANN THERAPIE-SYSTEME A.G.

Effective date: 20120228

REG Reference to a national code

Ref country code: NL

Ref legal event code: V1

Effective date: 20120901

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: EE

Ref legal event code: MM4A

Ref document number: E000732

Country of ref document: EE

Effective date: 20120228

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20120203

REG Reference to a national code

Ref country code: GR

Ref legal event code: ML

Ref document number: 20070400088

Country of ref document: GR

Effective date: 20120905

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120203

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120229

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120204

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120229

Ref country code: CZ

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120203

Ref country code: EE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120228

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20121031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120203

Ref country code: HU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120204

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120905

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120803

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 502004001897

Country of ref document: DE

Effective date: 20120901

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 344024

Country of ref document: AT

Kind code of ref document: T

Effective date: 20120203

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120229

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120203

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120203

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120203

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120901

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120203

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120901

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20130708

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120204

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120229

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120203

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120203